Cancer Worry Scale: Measuring Psychological Distress in Cancer Care
Cancer Worry Scale · Also known as: CWS
The Cancer Worry Scale (CWS) is a brief 8-item instrument assessing the degree to which cancer-related worry interferes with daily functioning and emotional well-being. Developed by Lerman et al. in 1991, it quantifies cancer-related anxiety and distress—psychological burden distinct from symptom burden and functional impairment. It is widely used in cancer screening, treatment, and survivorship contexts to identify patients requiring psychological support.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Cancer Worry Scale is indicated for cancer patients across disease stages and treatment contexts: at diagnosis (baseline psychological status), during active treatment (monitoring psychological adjustment), and in survivorship (post-treatment worry assessment). Primary use is oncology clinic screening for psychological distress and identification of patients needing mental health referral; secondary use in cancer psychology and quality-of-life research. Particularly valuable for brief, routine psychological screening in resource-constrained settings, identifying patients who might benefit from counseling, psychopharmacology, or structured supportive interventions.
Strengths & limitations
- Extremely brief (8 items, 2–3 minutes) enables routine clinic screening without substantial time burden.
- Specific to cancer-related worry, not general anxiety; directly relevant to cancer patient experience and concerns.
- Well-validated in large cancer patient cohorts across tumor types, treatment stages, and demographics.
- Low-cost, no licensing fees; publicly available and easy to administer.
- Established cutoff scores (≥14) identify clinically significant worry; useful for triage to psychological services.
- Single-item dimensional scale; does not distinguish types of worry (recurrence fear vs. treatment fear vs. death anxiety) or worry triggers.
- Does not assess depression, other mood disorders, or existential distress beyond cancer-specific worry.
- Brevity, while advantageous for screening, provides limited clinical detail; high scorers require supplementary psychological assessment.
- Cutoff scores (≥14) are population-derived estimates; optimal thresholds may vary by cancer type and clinical context.
Frequently asked
What is a clinically significant CWS score, and when should I refer for mental health care?
CWS ≥14 indicates moderate-to-significant cancer worry. Typical practice: refer for mental health evaluation if score ≥14, especially if patient reports worry interfering with daily function, sleep, or relationships. However, clinical judgment matters: a newly diagnosed patient with CWS=15 may not need immediate intervention if worry is normative and coping intact; a long-term survivor with CWS=18 may warrant more urgent psychological support. Use CWS as screening tool, not diagnostic criterion.
Can CWS be used to assess worry reduction after a psychological intervention?
Yes. CWS is sensitive to worry reduction following counseling, psychotherapy, or supportive interventions. Expected change: 3–5 point improvement reflects meaningful worry reduction; 10+ point improvement indicates substantial response. Serial CWS administration (baseline, post-intervention, follow-up) tracks intervention efficacy.
Is CWS specific to recurrence-related worry or does it capture all cancer-related worry?
CWS items address cancer-related worry broadly, including worry about recurrence, treatment side effects, prognosis, and death. It does not distinguish worry types; a high score could reflect recurrence fear, treatment fear, existential anxiety, or a combination. For detailed worry assessment, supplement with structured interviews or domain-specific scales (Fear of Recurrence Scale, existential distress measures).
Can CWS be used in cancer survivors long after treatment?
Yes. CWS is appropriate at any time post-diagnosis, including long-term survivors (5+ years). In stable survivors, CWS ≥14 may reflect residual recurrence fear, late-effect concerns, or second cancer anxiety. Interpretation: baseline worry typically declines over time post-treatment, so modest scores are expected in long-term survivors; rising scores warrant clinical attention.
What is the difference between CWS and general anxiety screening (GAD-7, HADS)?
CWS measures cancer-specific worry (cancer recurrence, prognosis, death). GAD-7 and HADS measure generalized anxiety, depression, and distress without cancer-specific focus. CWS is sensitive and specific to cancer contexts; better for cancer-specific screening. For comprehensive mental health assessment (generalized anxiety, depression), use GAD-7/HADS alongside CWS.
Is CWS publicly available and free to use?
Yes. Cancer Worry Scale is in the public domain, freely available, and requires no licensing. The 8-item instrument is widely published and reproducible. Use the original wording from Lerman et al. (1991) or subsequent publications to ensure consistency and validity.
Sources
- Lerman, C., Trock, B., Rimer, B. K., Jepson, C., Brody, D., & Boyce, A. (1991). Psychological side effects of breast cancer screening. Health Psychol, 10(1), 259–267. DOI: 10.1037/0278-6133.10.4.259 ↗
How to cite this page
ScholarGate. (2026, June 3). Cancer Worry Scale. ScholarGate. https://scholargate.app/en/oncology/cancer-worry-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- EORTC QLQ-LC13Oncology↔ compare
- FACT-ColorectalOncology↔ compare
- FACT-LungOncology↔ compare
- FACT-OvarianOncology↔ compare
- FACT-ProstateOncology↔ compare